Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Medpace Holdings, Inc. (Nasdaq: MEDP), a scientifically driven, global, full-service clinical contract research organization (CRO). Through these filings, investors can review the company’s official financial statements, risk disclosures, material agreements and other regulatory information that frame analysis of MEDP stock.
Medpace’s SEC reporting includes annual reports on Form 10-K, which contain audited financial statements, management’s discussion and analysis, and a detailed “Risk Factors” section describing uncertainties such as contract loss, backlog conversion, pricing pressure, international operations, regulatory compliance, and information systems risks. Quarterly reports on Form 10-Q provide interim financial updates and additional context on operating performance in the clinical research and development services business.
The company also files current reports on Form 8-K to disclose specific events. For example, Medpace has used Form 8-K to furnish earnings press releases under Item 2.02 and to describe amendments to its unsecured credit facility under Item 1.01, including changes to the aggregate principal amount available under its line of credit. These filings give detail on financing arrangements and other material developments beyond the headline numbers in press releases.
On Stock Titan, Medpace filings are paired with AI-powered summaries that highlight key points from lengthy documents, such as major changes in revenue and profitability, updates to guidance, or notable shifts in risk disclosures. Users can quickly scan 10-K and 10-Q reports, as well as 8-K items, while retaining the option to open the full SEC documents for deeper review. This page also surfaces information relevant to tracking management decisions, capital structure, and other regulatory matters that influence Medpace’s long-term profile as a global CRO.
Medpace Holdings (MEDP) – Form 4 insider transaction
CEO, Chairman and 10% owner August J. Troendle sold 48,487 common shares on 28-Jul-2025 at a weighted-average price of $451.69 (range $450.00-$454.96), yielding roughly $21.9 million in proceeds. The sale was executed via a limit order during an open trading window.
After the sale, Troendle still controls 962,615 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC—about 5.7 million shares in total—so his overall influence remains substantial. No derivative transactions were reported.
The transaction trims his direct stake by ~5%, but does not materially alter insider ownership or governance dynamics.
Medpace Holdings, Inc. (MEDP) filed a Form 144 indicating an intended sale of 7,500 common shares through Fidelity Brokerage Services. The shares have an aggregate market value of $3.38 million, implying a per-share reference price of roughly $450 based on the data provided.
• Approximate sale date: 07/28/2025 on Nasdaq
• Shares outstanding: 28,093,026, so the proposed sale represents about 0.03 % of shares outstanding.
• Shares were acquired on 10/24/2023 via stock-option exercise paid in cash.
• No other sales have been reported by this filer in the past three months.
The signer certified no undisclosed material adverse information and affirmed compliance with Rule 10b5-1, if applicable. No further financial results or company-level disclosures accompany this notice.
Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a proposed sale of up to 3,000 common shares through Fidelity Brokerage Services on or about 28 Jul 2025. At the filing’s stated aggregate market value of US$1.35 million, the sale equates to roughly US$450 per share and represents only about 0.01 % of the 28,093,026 shares outstanding.
The seller—whose name is not listed—acquired the shares directly from the issuer via three events: (i) vesting of 1,823 restricted shares on 28 Feb 2024, (ii) exercise of 1,000 stock-option shares on 6 May 2022, and (iii) exercise of 177 stock-option shares on 27 Oct 2020. No securities were sold by this person during the past three months, and the standard representation affirms no knowledge of undisclosed adverse information.
Because Form 144 is only a notice of intent, execution is not guaranteed. Given the modest size relative to the public float and absence of additional operational or financial disclosures, the filing is unlikely to be materially impactful for MEDP’s near-term fundamentals but does add a datapoint on insider sentiment.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
